TX-FLUENCE
11.8.2022 14:32:09 CEST | Business Wire | Press release
Fluence Bioengineering, Inc. (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, in collaboration with REMY, a horticultural lighting provider to Israel’s growing agriculture industry, is supporting the record introduction of lighting technology solutions to Israel’s medical cannabis facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005211/en/
Israel—considered a world leader in cannabis research, cultivation and advanced regulation—has positioned itself at the forefront of the $74 trillion global cannabis market through highly innovative technology and data applications. The country now boasts supply capabilities that surpass its domestic demand. As the Israeli market matures, more and more indoor farms are capitalizing on leading controlled environment agriculture strategies proven to optimize plant growth and profits.
REMY’s expertise, paired with Fluence’s products and evidence-based best practices for optimal lighting strategies at each phase of cannabis growth, has placed the companies’ collaborative designs in the three core categories of medical cannabis facilities in Israel: greenhouse, indoor and vertical farms.
Hybrid cultivation at Green Fields
Green Fields, which operates the largest medical cannabis growing facility in Israel, features a hybrid greenhouse model of harnessing sunlight and supplementing with artificial lighting to optimize plant quality. The forward-looking company chose Fluence and REMY to install a high-intensity lighting system.
"After working on several projects with REMY, we know the value of their professionalism, expertise and service. That's why we chose them for our flagship project," explained Jonathan Pisso, chief procurement officer of Green Fields. "The difference we saw in the first crop cycle using Fluence lighting was phenomenal. As a result of the facility's control system, we have a great deal of flexibility and maximum control. We have integrated all the technologies with an extremely powerful lighting system, which results in uniform growth and excellent results."
Growing indoors with Springs Valley Cannabis
Another popular type of cannabis facility in Israel is the fully indoor model, which allows control of all crop conditions to ensure uniform growth throughout the year while maximizing quality. Springs Valley Cannabis is setting up to become a major cannabis cultivator in Israel. It elected to use Fluence and REMY for lighting solutions in its indoor facility that covers an impressive 5,000 square meters of canopy.
"When we designed our unique facility, we sought trustworthy partners who would ensure our product would be a market leader. We found it in the combination of Fluence and REMY," said Yossi Shitrit, founder of Springs Valley Cannabis.
Trichome’s urban vertical farm
Located in the heart of an urban industrial area, Trichome operates a fully indoor, multi-tier vertical farming facility. Harnessing the power and control of indoor cultivation methods, Trichome searched for industry-leading partners with experience optimizing environmental parameters in a multi-tier environment. With Fluence’s SPYDR Series, Trichome leverages a high intensity, broad-spectrum strategy that delivers precise and uniform light to the plant canopy.
"Fluence’s and REMY's teams are extremely professional. They are dedicated to our success and bring us added value. The results are already exceeding our initial expectations," said Tony Levi, founder and CEO at Trichome. "It shows the potential for indoor growth in urban centers. The facility utilizes every square meter of the building for efficiency and uniformity."
"Israel is a technological 'playground' for the cannabis market, which makes it easy to examine and adopt advanced technologies quickly," said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. "With the early-adapter frame of mind that the Israeli industry practices, Fluence has managed to deliver expert horticulture knowledge and, together with REMY, cooperate with leading innovative growers to advance their operations."
In addition to providing lighting solutions, REMY specializes in the planning, installation, integration and quality assurance of large-scale agronomic solutions, as well as after-sales service and support.
"At the end of the day, the plant is the best indication for our success or failure—and we are achieving success in multiple, diverse cultivation environments," said Elad Toby, founder, CTO and chief business development officer for REMY.
To learn more about REMY, click here . To learn more about Fluence’s portfolio of luminaires and lighting controls, visit the company’s website here .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom